Nasdaq · Healthcare
ORASURE TECHNOLOGIES INC (OSUR)
As-reported financials and recent SEC filings for ORASURE TECHNOLOGIES INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$115.0M
Net income
$-68.7M
Net margin
-59.8%
Diluted EPS
$-0.94
ROE
-20.2%
P/E (TTM)
—
Market cap
$307.1M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $115.0M | $185.8M | $405.5M | $387.5M | $233.7M |
| Gross profit | $48.2M | $79.4M | $171.7M | $148.4M | $117.6M |
| Operating income | $-72.0M | $-28.3M | $32.7M | $-22.2M | $-10.2M |
| Net income | $-68.7M | $-19.5M | $53.7M | $-17.1M | $-23.0M |
| Diluted EPS | $-0.94 | $-0.26 | $0.72 | $-0.24 | $-0.32 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-11
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →8-K2026-06-03
View on EDGAR →Go deeper on OSUR
Search ORASURE TECHNOLOGIES INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.